Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Use of romiplostim for primary immune thrombocytopenia in children.

Escudero Vilaplana V, Aragonés JH, Fernández-Llamazares CM, Bieler CB, Rodríguez SM, Sáez MS.

Pediatr Hematol Oncol. 2012 Mar;29(2):197-205. doi: 10.3109/08880018.2011.629401.

PMID:
22376020
2.

Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.

Mokhtar GM, Tantawy AA, El Sherif NH.

Platelets. 2012;23(4):264-73. doi: 10.3109/09537104.2011.619601. Epub 2012 Apr 3.

PMID:
22471399
3.

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.

Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25.

PMID:
21706145
4.

An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.

Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2. Epub 2012 Apr 25.

PMID:
22532046
5.

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.

Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2014 Aug;39(4):376-82. doi: 10.1111/jcpt.12156. Epub 2014 Apr 4.

PMID:
24702274
6.

A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.

Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.

Eur J Haematol. 2017 Feb;98(2):112-120. doi: 10.1111/ejh.12807. Epub 2016 Sep 26.

PMID:
27557853
7.

Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.

Pasquet M, Aladjidi N, Guiton C, Courcoux MF, Munzer M, Auvrignon A, Lutz P, Ducassou S, Leroy G, Munzer C, Leverger G; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE).

Br J Haematol. 2014 Jan;164(2):266-71. doi: 10.1111/bjh.12609. Epub 2013 Oct 24.

PMID:
24152194
8.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
9.

Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.

Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.

Transfusion. 2016 Jan;56(1):73-9. doi: 10.1111/trf.13336. Epub 2015 Sep 24.

PMID:
26400824
10.

Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.

J Clin Pharm Ther. 2012 Dec;37(6):729-32. doi: 10.1111/j.1365-2710.2012.01353.x. Epub 2012 May 14.

PMID:
22583038
11.

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.

Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5.

PMID:
26537623
12.

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.

Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18.

PMID:
27103127
13.

Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.

Chouhan JD, Herrington JD.

Pharmacotherapy. 2010 Jul;30(7):666-83. doi: 10.1592/phco.30.7.666. Review.

PMID:
20575632
14.

Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP.

Mori M, Kato M, Koh K, Hanada R.

Rinsho Ketsueki. 2015 May;56(5):511-3. doi: 10.11406/rinketsu.56.511.

PMID:
26062675
15.

Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.

Meletis J, Katsandris A, Raptis SD, Mantzourani M.

Med Sci Monit. 2010 Aug;16(8):CS100-2.

PMID:
20671616
16.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.

Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45. doi: 10.1182/blood-2011-03-340166. Epub 2011 Aug 10.

17.

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.

Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.

PMID:
23432528
18.

Romiplostim: a review of its use in immune thrombocytopenia.

Keating GM.

Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Review.

PMID:
22316355
19.

Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.

Elalfy MS, Abdelmaksoud AA, Eltonbary KY.

Ann Hematol. 2011 Nov;90(11):1341-4. doi: 10.1007/s00277-011-1172-9. Epub 2011 Feb 12.

PMID:
21318572
20.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.

Supplemental Content

Support Center